The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
Type 2 diabetes is characterized by increasing incidence and prevalence all-over the world. Current therapeutic management of type 2 diabetes is complex and is based not only on glycemic control, but also on cardiovascular and renal risks reduction. In previous years the use of sodium-glucose cotran...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2023-05-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13034 |
| _version_ | 1797255101981655040 |
|---|---|
| author | M. B. Antsiferov G. R. Galstyan T. Yu. Demidova A. V. Zilov T. N. Markova А. M. Mkrtumyan N. A. Petunina I. S. Khalimov M. S. Shamkhalova M. V. Shestakova |
| author_facet | M. B. Antsiferov G. R. Galstyan T. Yu. Demidova A. V. Zilov T. N. Markova А. M. Mkrtumyan N. A. Petunina I. S. Khalimov M. S. Shamkhalova M. V. Shestakova |
| author_sort | M. B. Antsiferov |
| collection | DOAJ |
| description | Type 2 diabetes is characterized by increasing incidence and prevalence all-over the world. Current therapeutic management of type 2 diabetes is complex and is based not only on glycemic control, but also on cardiovascular and renal risks reduction. In previous years the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) increased in Russian Federation. Some manufacturers of the most widely used GLP-1 RA reported the supply decline in several countries. On Advisory board with participation of the Russian Endocrinology Association members the topics of SGLT2i and GLP-1 RA use in type 2 diabetes were discussed. The experts made conclusion that the decrease in access to GLP-1 RA does not pose serious risk for treatment of type 2 diabetes patients. SGLT2i show benefits in risk reduction of HF and CKD progression compering to GLP-1 RA, and in general show comparable efficacy in risk reduction of ACVD outcomes. SGLT2i show less glycemic efficacy in comparison with GLP-1 RA, and their replacement may need adding antidiabetic agents from other groups. |
| first_indexed | 2024-03-08T15:19:40Z |
| format | Article |
| id | doaj.art-d859b678f86d4281a70004385fe60c28 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:00:30Z |
| publishDate | 2023-05-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-d859b678f86d4281a70004385fe60c282024-03-20T11:48:05ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782023-05-0126221121410.14341/DM1303411014The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetesM. B. Antsiferov0G. R. Galstyan1T. Yu. Demidova2A. V. Zilov3T. N. Markova4А. M. Mkrtumyan5N. A. Petunina6I. S. Khalimov7M. S. Shamkhalova8M. V. Shestakova9Endocrinological DispensaryEndocrinology Research CentrePirogov Russian National Research Medical UniversityI.M. Sechenov First Moscow State Medical UniversityA.I. Yevdokimov Moscow State University of Medicine and DentistryA.I. Yevdokimov Moscow State University of Medicine and DentistryI.M. Sechenov First Moscow State Medical UniversityMilitary Medical Academy named after S.M. KirovEndocrinology Research CentreEndocrinology Research CentreType 2 diabetes is characterized by increasing incidence and prevalence all-over the world. Current therapeutic management of type 2 diabetes is complex and is based not only on glycemic control, but also on cardiovascular and renal risks reduction. In previous years the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) increased in Russian Federation. Some manufacturers of the most widely used GLP-1 RA reported the supply decline in several countries. On Advisory board with participation of the Russian Endocrinology Association members the topics of SGLT2i and GLP-1 RA use in type 2 diabetes were discussed. The experts made conclusion that the decrease in access to GLP-1 RA does not pose serious risk for treatment of type 2 diabetes patients. SGLT2i show benefits in risk reduction of HF and CKD progression compering to GLP-1 RA, and in general show comparable efficacy in risk reduction of ACVD outcomes. SGLT2i show less glycemic efficacy in comparison with GLP-1 RA, and their replacement may need adding antidiabetic agents from other groups.https://www.dia-endojournals.ru/jour/article/view/13034type 2 diabetessodium-glucose cotransporter 2 inhibitorsglucagon-like peptide 1 receptor agonistscomparability |
| spellingShingle | M. B. Antsiferov G. R. Galstyan T. Yu. Demidova A. V. Zilov T. N. Markova А. M. Mkrtumyan N. A. Petunina I. S. Khalimov M. S. Shamkhalova M. V. Shestakova The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes Сахарный диабет type 2 diabetes sodium-glucose cotransporter 2 inhibitors glucagon-like peptide 1 receptor agonists comparability |
| title | The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes |
| title_full | The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes |
| title_fullStr | The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes |
| title_full_unstemmed | The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes |
| title_short | The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes |
| title_sort | advisory board resolution on the use of sodium glucose cotransporter 2 inhibitors and glucagon like peptide 1 receptor agonists in type 2 diabetes |
| topic | type 2 diabetes sodium-glucose cotransporter 2 inhibitors glucagon-like peptide 1 receptor agonists comparability |
| url | https://www.dia-endojournals.ru/jour/article/view/13034 |
| work_keys_str_mv | AT mbantsiferov theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT grgalstyan theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT tyudemidova theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT avzilov theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT tnmarkova theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT ammkrtumyan theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT napetunina theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT iskhalimov theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT msshamkhalova theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT mvshestakova theadvisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT mbantsiferov advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT grgalstyan advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT tyudemidova advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT avzilov advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT tnmarkova advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT ammkrtumyan advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT napetunina advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT iskhalimov advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT msshamkhalova advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes AT mvshestakova advisoryboardresolutionontheuseofsodiumglucosecotransporter2inhibitorsandglucagonlikepeptide1receptoragonistsintype2diabetes |